Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
PDL BioPharma, Inc.
Type
Public
Traded as NASDAQ: PDLI
Industry Biotechnology
Key people

John McLaughlin (CEO)
Peter Garcia (CFO)
Cary Queen (Founder, former vice-president in charge of research)

Lawrence J. Korn (Founder, former president)
Revenue $590.4 million (2015)
Website pdl.com

PDL BioPharma (known as Protein Design Labs prior to 2006) is a publicly traded American holding company that since 2008 manages patents and other intellectual property that had been generated by the company. In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million.

Protein Design Labs had been founded in 1986 and was a pioneer in humanizing monoclonal antibodies. Its humanization technology was used in several monoclonal antibody drugs under licensing and collaboration agreements; such products included rituximab (Rituxan), bevacizumab (Avastin), and palivizumab (Synagis). It held its initial public offering in 1992 and by 1994 it had 13 compounds in its pipeline, and had partnered its lead product, the humanized monoclonal antibody daclizumab, with Roche under a license that called for a 15% royalty. Daclizumab became the first humanized monoclonal antibody approved for human use in 1997. PDL made another public offering in 2000, at the peak of the biotech IPO window that ran from 1998 to 2001. In 2003 it settled litigation with Genentech over royalty payments owed to PDL under their license agreement; annual royalties were anticipated at that time to be around $90M per year. These are the kinds of intellectual property and license agreements that PDL manages on behalf of its shareholders since 2008; in 2007 those royalty payments were around $220 million.

One of the development programs that PDL had transferred to Facet was the use of daclizumab in indications it had never licensed to Roche, including multiple sclerosis. Facet partnered that development program with Biogen Idec which attempted a hostile buy out of Facet for $350M in 2009; Facet rejected that offer and was purchased by Abbvie for $450 million in cash the next year. The FDA approved daclizumab for multiple sclerosis in 2016 under the trade name Zinbryta.

Investment goal date:
Dividends reinvested
PDL BioPharma, Inc. PDLI report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-04
--
--
Q4 2017
2018-02-21
--
--
Q3 2017
2017-11-02
--
--
Q3 2017
2017-11-02
0.1400
0.1400
Q2 2017
2017-08-03
0.3900
0.3900
Q1 2017
2017-05-03
0.0400
0.0400
Q4 2016
2017-03-01
0.2900
-0.0600
Q3 2016
2016-11-03
0.0800
0.0800
Q2 2016
2016-08-04
0.0300
0.0300
Q1 2016
2016-05-04
0.3400
0.3400
Q4 2015
2016-02-22
0.6200
0.6100
Q3 2015
2015-11-04
0.4200
0.4200
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
ACADIAN ASSET MANAGEMENT LLC
4825688
BlackRock Fund Advisors
7359385
BlackRock Inc.
14384646
BlackRock Institutional Trust Company, N.A.
5819729
CITADEL ADVISORS LLC
5528172
DIMENSIONAL FUND ADVISORS LP
5683650
GEODE CAPITAL MANAGEMENT, LLC
2139365
Invesco Ltd.
2385448
MACKENZIE FINANCIAL CORP
4818609
RENAISSANCE TECHNOLOGIES LLC
12036754
ROYAL BANK OF CANADA
3473956
RUSSELL FRANK CO/
2670761
SCHWAB CHARLES INVESTMENT MANAGEMENT INC
2292624
STATE STREET CORP
4409212
Vanguard Group, Inc
14180118
Major Shareholders
Name Relationship
Total Shares
Holding stocks
SAXE JON S
0.2600% (421680)
DRRX / PDLI / SCLN / VTGN /
FRANK FRED
0.0200% (33296)
LNDC / PDLI /
GARCIA PETER S
0.2900% (472842)
BTX / MRNA / PDLI /
SANDMAN PAUL W
0.1300% (208452)
PDLI /
GAGE L PATRICK
0.0100% (19555)
CYTK / PDLI / TTPH /
GRYSKA DAVID W
0.1000% (165163)
KLEIN JOSEPH III
0.0100% (16983)
ISIS / PDLI /
GUGGENHIME ANDREW
0.0100% (13255)
DERM / PDLI /
SHAH JAISIM
0.0100% (16125)
PDLI / SRNE /
MURRAY RICHARD /CA/
0.0400% (70159)
PDLI /
WILSON KAREN J
0.0100% (10494)
JAZZ / PDLI /
LARSON CHRISTINE R
0.0400% (62049)
DVAX / PDLI /
MCLAUGHLIN JOHN PETER
0.8700% (1404463)
AAVL / PDLI / SGEN /
SELICK HAROLD E
0.1300% (202480)
PDLI / PTGX / THLD / TRGT /
Hasnain Faheem
0.0800% (125000)
AMBI / PDLI / RCPT / VTL /
Lindell Jody S
0.1300% (201826)
COO / PDLI /
Saks Samuel R
0.1000% (159842)
ASPX / DEPO / PDLI / TNXP /
McCamish Mark Anthony
0.0100% (14924)
PDLI /
Stone Christopher Lewis
0.2800% (448746)
PDLI /
KRUMEL CAROLINE J
0.0100% (9384)
PDLI /
Hart Danny J Jr.
0.2400% (387236)
PDLI /
Edick Paul R
0.1000% (160215)
Tomlinson Bruce
0.0100% (16509)
PDLI /
Montez David
0.0200% (26719)
PDLI /
Monnet Dominique
0.1500% (240200)
ALXN / PDLI /
% ()